Based in Austin, TX but with facilities also in California, Curtana Pharmaceuticals is a biopharmaceutical company developing small molecule therapeutics. These therapeutics are specifically designed to target cancer stem cells in the central nervous systems (CNS) that can be used to treat various forms of brain cancer. Curtana's focus thus far has been on the treatment of glioblastoma (GBM), the most common and deadly form of brain tumor found in adults. Curtanaâs OLIG2 inhibitor proteins may also be effective in treating melanoma and pre-T-cell leukemia as well as some small cell lung cancers and breast cancers. The company was founded on the research of Dr. Santosh Kesari at the University of California San Diego School of Medicine's Moores Cancer Center
